1. Cellular Origins. Cellular Origins and Cell and Gene Therapy Catapult collaborate to demonstrate universal automation of CGT manufacturing. 2024. https://cellularorigins.com/news/cellular-origins-and-cell-and-gene-therapy-catapult-collaborate-to-demonstrate-universal-automation-of-cgt-manufacturing/
2. Astellas. Astellas Announces a Collaboration with YASKAWA to Create an Innovative Cell Therapy Ecosystem through the Integration of Pharmaceutical and Robotics Technologies. 2024. http://www.astellas.com/en/news/29201
3. Cellipoint Bioservices. Cellipont Bioservices and Adva Biotechnology Collaborate to Optimize Cell Therapy Manufacturing with the ADVA X3® Platform 2024. https://cellipont.com/news/cellipont-bioservices-and-adva-biotechnology-collaborate-to-optimize-cell-therapy-manufacturing-with-the-adva-x3-platform/
4. Galapagos. Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune's TCR T-cell therapy candidate uza-cel in head & neck cancer and potential future solid tumor indications 2024. http://www.glpg.com/press-releases/galapagos-and-adaptimmune-sign-clinical-collaboration-agreement-with-an-option-to-exclusively-license-adaptimmunes-tcr-t-cell-therapy-candidate-uza-cel-in-head-neck-cancer-and-potential-f/
5. NCT04044859. ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS). https://clinicaltrials.gov/study/NCT04044859